Alvotech (ALVO) said Thursday it is acquiring Xbrane Biopharma's R&D operations and biosimilar candidate XB003 for about 275 million Swedish krona ($27.2 million).
The acquisition, which is expected to close in April, includes Xbrane's R&D operations in Campus Solna, Sweden. Xbrane will retain other pre-clinical assets.
Alvotech also said it plans to explore a potential listing of Swedish depository receipts on Nasdaq Stockholm in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。